Psychiatric Associates — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$12,882	4
2024	Research	$10,201	4
2023	Research	$211,977	39
2022	Research	$241,663	43
2021	Research	$145,852	24
2020	Research	$342,365	53
2019	Research	$247,015	61

Breakdown

Who paid Research payments · program years 2019–2025

Supernus Pharmaceuticals, Inc. $650,067 94 payments
Allergan Inc. $218,092 43 payments
AbbVie, Inc. $157,814 40 payments
ITI, Inc. $150,171 36 payments
Shire North American Group Inc $17,041 9 payments
Sunovion Pharmaceuticals Inc. $16,779 4 payments
Takeda Pharmaceuticals U.S.A., Inc. $1,990 2 payments

Studies the money was for Research payments · program years 2019–2025

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Spn-812 in Adults With Attention- Deficit/Hyperactivity Disorder $122,838 17 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of Spn-812 in Adults With Attention-Deficit/Hyperactivity Disorder (Adhd) $119,345 11 payments
Phase 4 (PMR Pediatric Gad) $112,386 18 payments
A Phase IV, Open-Label, Flexible-Dose Safety Trial Evaluating Spn-812 Administered With Psychostimulants in Children and Adolescents (6 to 17 Years of Age) With Disorder (Adhd) Attention-Deficit/Hyperactivity $103,714 7 payments
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $93,040 19 payments
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $77,653 17 payments
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $67,181 18 payments
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $62,052 12 payments
Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Subjects With Attention Deficithyperactivity Disorder $56,673 12 payments
An Open-Label Multicenter Trial to Assess the Safety and Tolerability of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $50,948 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.